Breast cancers with HER2/ERBB amplification respond to trastuzumab and/or lapatinib, and tumors with mutated or amplified BCR-ABL (breakpoint cluster region C-ABL oncogene 1, non-receptor tyrosine kinase) respond to imatinib mesylate[40]. Here, EGFR is linked to breast carcinoma.